Document:

Exhibit 10.2

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY
NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM,
THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. 

 

_______________________________

 

BIONIK LABORATORIES CORP.

 

SECURED CONVERTIBLE PROMISSORY NOTE

 

	Principal Amount: US$[___]	Issue Date: June [__], 2019

 

Bionik
Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises
to pay to [_____] or its permitted assigns or successors (the “Holder”), the principal amount of [_____]
Dollars (US$[___]) (the “Principal Amount”), without demand, on the Maturity Date (as hereinafter defined),
together with any accrued and unpaid interest due thereon. This Note shall bear interest at a fixed rate of 1% per month, beginning
on the Issue Date. Interest shall be computed based on a 360-day year of twelve 30-day months and shall be payable, along with
the Principal Amount, on the Maturity Date. Except as set forth in Section 3.1, payment of all principal and interest due
shall be in such coin or currency of the United States of America as shall be legal tender for the payment of public and private
debts at the time of payment.

 

This Note is a convertible
promissory note referred to in that certain Subscription Agreement dated as of the date hereof, or series of like subscription
agreements (individually or collectively, the “Subscription Agreement”), among the Company and the subscribers
named therein, pursuant to which the Company is seeking to borrow up to $9,000,000 (the “Offering”).

 

1.       Definitions.

 

1.1       Definitions.
The terms defined in this Section 1 whenever used in this Note shall have the respective meanings hereinafter specified.

 

“Change
in Control” means a merger or consolidation of the Company with or into any other entity in which the stockholders
of the Company immediately prior to the merger or consolidation do not own more than 50% of the outstanding voting power (assuming
conversion of all convertible securities and the exercise of all outstanding options and warrants) of the surviving entity or the
sale, lease, licensing, transfer or other disposition of all or substantially all the assets of the Company; provided, however,
that any new issuance of capital stock (or securities convertible or exercisable into capital stock) of the Company to one or more
third parties for the sole purpose of providing funding for the Company shall not constitute a Change in Control.

 

    1

     

    

 

“Collateral”
shall mean and include all machinery, equipment, furniture, furnishings, tools, tooling, fixtures, and accessories, and all inventory,
accounts receivable, instruments, contract rights and other rights to receive the payment of money, patents, chattel paper, licenses,
leases and general intangibles, including all trade names and trade styles and all additions, accessions, modifications, improvements,
replacements and substitutions thereto and therefor, whether now owned or hereafter acquired or arising, and the proceeds, products
and income of any of the foregoing, including insurance proceeds.

 

“Common
Stock” means the common stock, par value $0.001 per share, of the Company.

 

“Conversion
Shares” means the Common Stock issued or issuable to the Holder pursuant to Article 3.

 

“Event
of Default” shall have the meaning set forth in Section 6.1.

 

“Holder”
or “Holders” means the person named above or any Person who shall thereafter become a recordholder of
this Note in accordance with the terms hereof.

 

“Issue
Date” means the issue date stated above.

 

“Maturity
Date” shall mean the earlier of (a) March 30, 2020, and (b) the consummation of a Qualified Financing.

 

“Note”
means this Convertible Note, as amended, modified or restated.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization
or any government, governmental department or agency or political subdivision thereof.

 

“Qualified
Financing” means the Offering, provided that the Company raises in one or more tranches aggregate gross proceeds
of no less than US$9,000,000.

 

“Securities
Act” means the United States Securities Act of 1933, as amended.

 

2.       GENERAL
PROVISIONS.

 

2.1       Loss,
Theft, Destruction of Note. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or
mutilation of this Note and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security reasonably
satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation of this Note, the Company
will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a new Note of like tenor and unpaid principal
amount dated as of the date hereof. This Note shall be held and owned upon the express condition that the provisions of this Section
2.1 are exclusive with respect to the replacement of a mutilated, destroyed, lost or stolen Note and shall preclude any and
all other rights and remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to
the replacement of negotiable instruments or other securities without their surrender.

 

2.2       Prepayment;
Redemption. This Note may not be prepaid by the Company in whole or in part, except with the prior written consent of
the Holder. This Note may not be redeemed by the Company in whole or in part, except with the prior written consent of the Holder.

 

    2

     

    

 

3.       CONVERSION
OF NOTE.

 

3.1       Conversion.

 

(a)       Conversion
upon Maturity Date. On the Maturity Date without any action on the part of the Holder, the outstanding principal and accrued
and unpaid interest under the Notes will be converted into shares of Common Stock at a conversion price of US$6.80 per share (the
“Conversion Price”).

 

(b)       Conversion
upon Change of Control. If a Change of Control transaction occurs prior to the Maturity Date, the outstanding principal and
accrued and unpaid interest under the Note would, at the election of the holders of a majority of the outstanding principal of
the Notes, be either (i) payable upon demand as of the closing of such Change of Control transaction or (ii) convertible into shares
of the Common Stock immediately prior to such Change of Control transaction at a price per share equal to the lesser of (x) the
Conversion Price, or (y) the per share consideration to be received by the holders of the Common Stock in such Change of Control
transaction.

 

(c)       Cancellation.
Upon and as of the Maturity Date, this Note will be cancelled on the books and records of the Company and shall solely represent
the right to receive the Conversion Shares.

 

3.2       Delivery
of Securities Upon Conversion.

 

(a)       As
soon as is practicable after the Maturity Date or an event pursuant to Section 3.1(b)(ii), the Company shall deliver to the Holder
a certificate or certificates evidencing the Conversion Shares issuable to the Holder.

 

(b)       The
issuance of certificates for Conversion Shares upon conversion of this Note shall be made without charge to the Holder for any
issuance tax in respect thereof or other cost incurred by the Company in connection with such conversion and the related issuance
of securities. Upon conversion of this Note, the Company shall take all such actions as are necessary in order to ensure that the
Conversion Shares so issued upon such conversion shall be validly issued, fully paid and nonassessable.

 

3.3       Fractional
Shares. No fractional shares or scrip representing fractional shares shall be issued upon conversion of this Note. If
any conversion of this Note would create a fractional share or a right to acquire a fractional share, the Company shall round to
the nearest whole number.

 

3.4       Anti-Dilution. 
In the event this Note converts into Common Stock pursuant to Section 3.1(a) and the Company raises capital through the sale of
Common Stock for cash during the period ending on the three (3) year anniversary of the earliest Issue Date of the Related Notes
(for the avoidance of doubt, including this Note), and the price per share thereof (the “Offering Price”)
is less than the Conversion Price, then in such event the Company shall issue to the Holder, at no further cost to the Holder,
additional shares of Common Stock equal to the number of Conversion Shares the Holder would have received upon conversion if the
Conversion Price equaled the Offering Price, less the number of shares of Conversion Shares actually issued on or as of the Maturity
Date.

 

    3

     

    

 

4.       COLLATERAL.

 

4.1       Security
Interest In The Collateral.  To secure the prompt payment and performance to Holder of the obligations hereunder,
the Company hereby assigns, pledges and grants to Holder a continuing security interest in and to, and lien on, all of its Collateral.

 

4.2       Perfection
Of Security Interest.  The Company shall take all action that may be necessary or desirable, or that Holder may
request, so as at all times to maintain the validity, perfection, enforceability and priority of Holder’s security interest
in and lien on the Collateral or to enable Holder to protect, exercise or enforce its rights hereunder and in the Collateral. 
By its signature hereto, the Company hereby authorizes Holder to file against the Company one or more financing, continuation or
amendment statements pursuant to the Uniform Commercial Code in form and substance reasonably satisfactory to Holder.

 

5.       STATUS;
RESTRICTIONS ON TRANSFER.

 

5.1       Status
of Note. This Note is a direct, general and unconditional obligation of the Company, and constitutes a valid and legally
binding obligation of the Company, enforceable in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other similar laws of general applicability relating to or affecting creditors’ rights and to general
principles of equity. This Note does not confer upon the Holder any right to vote or to consent or to receive notice as a stockholder
of the Company, as such, in respect of any matters whatsoever, or any other rights or liabilities as a stockholder, prior to conversion
hereof into Conversion Shares.

 

5.2       Restrictions
on Transferability. This Note and any Conversion Shares issued with respect to this Note, have not been registered under
the Securities Act, or under any state securities or so-called “blue sky laws,” and may not be offered, sold, transferred,
hypothecated or otherwise assigned except (a) pursuant to a registration statement with respect to such securities which is effective
under the Act or (b) upon receipt from counsel satisfactory to the Company of an opinion, which opinion is satisfactory in form
and substance to the Company, to the effect that such securities may be offered, sold, transferred, hypothecated or otherwise assigned
(i) pursuant to an available exemption from registration under the Act and (ii) in accordance with all applicable state securities
and so-called “blue sky laws.” The Holder agrees to be bound by such restrictions on transfer. The Holder further consents
that the certificates representing the Conversion Shares that may be issued with respect to this Note may bear a restrictive legend
to such effect.

 

5.3       COVENANTS.
In addition to the other covenants and agreements of the Company set forth in this Note, the Company covenants and agrees that
so long as this Note shall be outstanding, if any one or more events occur which constitute or which, with the giving of notice
or the lapse of time or both, would constitute an Event of Default or if the Holder shall demand payment or take any other action
permitted upon the occurrence of any such Event of Default, the Company will forthwith give notice to the Holder, specifying the
nature and status of the Event of Default or other event or of such demand or action, as the case may be.

 

    4

     

    

 

6.       REMEDIES.

 

6.1       Events
of Default. “Event of Default” wherever used herein means any one of the following events:

 

(a)       The
Company shall fail to issue and deliver the Conversion Shares in accordance with Section 3;

 

(b)       Default
in the due and punctual payment of the principal of, or any other amount owing in respect of (including interest), this Note when
and as the same shall become due and payable;

 

(c)       Default
in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant or agreement a
default in the performance of which is specifically provided for elsewhere in this Section 6.1), and the continuance of
such default for a period of 10 days after there has been given to the Company by the Holder a written notice specifying such default
and requiring it to be remedied;

 

(d)       The
entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving as properly
filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under the Federal
Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee or sequestrator
(or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation
of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar days;

 

(e)       The
institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of
bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization
or relief under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to the filing of
any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official)
of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors;

 

(f)       The
Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an arrangement or
composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension of payments
or other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting all or any
material part of the indebtedness of the Company; or

 

(g)       It
becomes unlawful for the Company to perform or comply with its obligations under this Note.

 

    5

     

    

 

6.2       Effects
of Default. If an Event of Default occurs and is continuing, then and in every such case the Holder may declare this
Note to be due and payable immediately, by a notice in writing to the Company, and upon any such declaration, the Company shall
pay to the Holder the outstanding principal amount of this Note plus all accrued and unpaid interest through the date the Note
is paid in full. Holder shall further have the right to exercise any and all rights and remedies provided for herein, under the
Uniform Commercial Code and at law or equity generally, including the right to foreclose the security interests granted herein
and to realize upon any Collateral by any available judicial procedure and/or to take possession of and sell any or all of the
Collateral with or without judicial process. Holder may enter the Company’s premises without legal process and without incurring
liability to the Company therefor, and Holder may thereupon, or at any time thereafter, in its discretion without notice or demand,
take the Collateral and remove the same to such place as Holder may deem advisable and Holder may require the Company to make the
Collateral available to Holder at a convenient place.

 

6.3       Remedies
Not Waived; Exercise of Remedies. No course of dealing between the Company and the Holder or any delay in exercising
any rights hereunder shall operate as a waiver by the Holder. No failure or delay by the Holder in exercising any right, power
or privilege under this Note shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other
or further exercise thereof or the exercise of any other right, power or privilege. By acceptance hereof, the Holder acknowledges
and agrees that this Note is one of a series of Convertible Promissory Notes of similar tenor issued by the Company pursuant to
the Offering (collectively, the “Related Notes”) and that upon the occurrence and during the continuance
of any Event of Default, the holders of a majority in original principal amount of the Related Notes, including this Note, shall
have the right to act on behalf of the holders of all such Notes in exercising and enforcing all rights and remedies available
to all of such holders under this Note, including, without limitation, foreclosure of any judgment lien on any assets of the Company.
By acceptance hereof, the Holder agrees not to independently exercise any such right or remedy without the consent of the holders
of a majority in original principal amount of the Related Notes (for the avoidance of doubt, including this Note).

 

7.       MISCELLANEOUS.

 

7.1       Severability.
If any provision of this Note shall be held to be invalid or unenforceable, in whole or in part, neither the validity nor the enforceability
of the remainder hereof shall in any way be affected.

 

7.2       Notice.
Where this Note provides for notice of any event, such notice shall be given (unless otherwise herein expressly provided) in writing
and either (a) delivered personally, (b) sent by certified, registered or express mail, postage prepaid or (c) sent by facsimile
or other electronic transmission, and shall be deemed given when so delivered personally, sent by facsimile or other electronic
transmission (confirmed in writing) or mailed. Notices shall be addressed, if to Holder, to its address as provided in the Subscription
Agreement or, if to the Company, to its principal office.

 

7.3       Governing
Law. This Note shall be governed by, and construed in accordance with, the laws of the State of Delaware (without giving
effect to any conflicts or choice of law provisions that would cause the application of the domestic substantive laws of any other
jurisdiction).

 

    6

     

    

 

7.4       Forum.
The Holder and the Company hereby agree that any dispute which may arise out of or in connection with this Note shall be adjudicated
before a court of competent jurisdiction in the State of Delaware and they hereby submit to the exclusive jurisdiction of the courts
of the State of Delaware, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, with respect
to any action or legal proceeding commenced by either of them and hereby irrevocably waive any objection they now or hereafter
may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is
an inconvenient forum.

 

7.5       Headings.
The headings of the Articles and Sections of this Note are inserted for convenience only and do not constitute a part of this Note.

 

7.6       Amendments.
This Note may be amended or waived only with the written consent of the Company and the holders of a majority in original aggregate
principal amount of this Note and the other Related Notes. Any such amendment or waiver shall be binding on all holders of the
Notes, even if they do not execute such consent, amendment or waiver.

 

7.7       No
Recourse Against Others. The obligations of the Company under this Note are solely obligations of the Company and no
officer, employee or stockholder shall be liable for any failure by the Company to pay amounts on this Note when due or perform
any other obligation.

 

7.8       Assignment;
Binding Effect. This Note may be assigned by the Company without the prior written consent of the Holder. This Note
shall be binding upon and inure to the benefit of both parties hereto and their respective permitted successors and assigns.

 

Signature
on the Following Page

 

    7

     

    

 

In
Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove
written.

 

	 	Bionik Laboratories Corp.	 
	 	 	 
	 	 	 
	 	By:	                    	 
	 	Name: Eric Dusseux	 
	 	Title:   CEO	 

 

    
Signature Page to Convertible Promissory NoteBlueprint

  Exhibit 10.1

 

DEED OF TERMINATION OF JOINT VENTURE AGREEMENT

 

 

 

This
Deed of Termination of Joint Venture Agreement (“Deed”) is made on this
4th day of June 2019 (the “Effective Date”), by and
among:

 

SANUWAVE
Health, Inc., a company incorporated in the State of Nevada, U.S.A.
and located at 3360 Martin Farm Road, Suite 100, Suwanee, GA 30024
U.S.A (“SANUWAVE”).

 

Johnfk
Medical, Inc., a company incorporated in Taiwan and located at 7
-8F, No. 919, Zhongzheng Road, Shonghe Dist., New Taipei City 235,
Taiwan (“JohnFK”).

 

And

 

Holistic
Health Institute Pte. Ltd, an exempt private limited company
incorporated in the Republic of Singapore, company number
201838185F with a registered address at 6 Temasek Boulevard,
#09-05, Suntec Tower Four, Singapore (038986) (the
“Company”).

 

*referred to in the
JV Agreement (as defined below) as “Holistic Health Institute
Pte. Ltd (with such company name subject to confirmation by
Singapore Government)”

 

SANUWAVE,
JohnFK and the Company are individually referred to as such or as a
“Party,” and are
collectively referred to as the “Parties,” in this
Deed.

 

WHEREAS:

 

A.

The Parties entered
into that certain Joint Venture Agreement dated as of September 21,
2018 (as amended, the “JV Agreement”) to
establish the Company as a joint venture (the “JV”) for undertaking the
business to (a) sell, rent and distribute SANUWAVE’s
dermaPACE® and orthoPACE® devices (the
“Products”)
in the territory comprising Taiwan, Singapore, Malaysia, Brunei,
Cambodia, Myanmar, Laos, Indonesia, Thailand, the Philippines,
Vietnam and such additional regions of Southeast Asia (if any)
agreed to from time to time among the Parties (the
“Territory”); (b)
refurbish and maintain applicators for usage by clients in the
Territory, and (c) carry on such other businesses and activities in
the Territory and make other investments as may be approved by the
Board (as defined in the JV Agreement) from time to time
(collectively, the “Business”).

 

B.

SANUWAVE and JohnFK
have held discussions pursuant to which JohnFK has agreed and
consented to:

Pay
SANUWAVE the outstanding amount of $63,275 USD for equipment
delivered to JohnFK (See Exhibit A hereto for copy of
outstanding invoices) (the “Equipment
Payment”).

 

Pay
SANUWAVE a penalty fee of $50,000 USD for early termination of the
JV Agreement (See Exhibit B hereto for copy of
penalty fee invoice) (the “Early Termination
Payment”).

 

C.

The Parties desire
by this Deed to terminate the JV and the JV Agreement and to
provide for the liquidation of the Company as soon as reasonably
practicable following the execution and delivery of this Deed by
the Parties, all subject to the terms and conditions detailed
hereunder.

 

NOW
THEREFORE, in consideration of the mutual covenants herein
contained, and other good and valuable consideration the receipt
and adequacy of which is hereby acknowledged, the Parties agree as
follows:

 

1.

 Termination and Liquidation.
The JV Agreement is hereby terminated. Each of SANUWAVE and JohnFK
hereby waives its rights under the first sentence of Section 7.3 of
the JV Agreement and authorizes the winding down and liquidation of
the Company as soon as reasonably practicable following the
Effective Date. Subject to applicable laws governing distributions
in liquidation, all distributions in liquidation, if any, to
SANUWAVE and JohnFK shall be made in accordance with Section 7.3 of
the JV Agreement. Each Party agrees that it will reasonably
cooperate with each other Party in order to ensure an orderly
winding down and liquidation of the Company. Without limitation of
any other provision of this Deed, in connection with the winding
down and liquidation of the Company, each of the Company and JohnFK
(i) shall return to SANUWAVE all proprietary information and
materials of SANUWAVE, and all copies and other manifestations
thereof, relating to the Products, and (ii) at its sole expense
shall execute, acknowledge, attest, certify and deliver any and all
assignments, certificates, instruments and documents reasonably
requested by SANUWAVE from time to time in order to effect the
assignment to or obtaining by SANUWAVE of any and all
registrations, licenses and permissions necessary to the
importation, promotion, marketing, sale, rental, distribution
and/or servicing of the Products and related technology and
intellectual property within the Territory or any part thereof
(excluding such as possessed by JohnFK with respect to Taiwan,
subject to the execution and delivery by SANUWAVE and JohnFK of the
Distribution Agreement (as hereinafter defined).

 

 

1

 

 

2.

Rights and Licenses. Without
limiting the generality of the foregoing, all rights and licenses
granted by SANUWAVE to the Company and/or JohnFK under the JV
Agreement or otherwise in connection with the JV with respect to
the Products and to any intellectual property rights therein,
including, but not limited to, rights and licenses to import,
promote, market, sell, rent, distribute and/or service the Products
in the Territory and to use and display the trademarks of SANUWAVE
in connection with such activities, are hereby terminated. The
Parties agree that SANUWAVE is and shall remain the sole and
absolute owner of the Products and of any and all improvements,
modifications, updates, upgrades and enhancements thereto made by
any Party during the term of the JV Agreement, and of all
technology and intellectual property rights relating thereto. All
registrations of the Products obtained by or on behalf of the
Company and/or JohnFK in the Territory shall belong solely to, and
are hereby assigned and conveyed by the Company and JohnFK to,
SANUWAVE, and may be assigned by SANUWAVE to any other person or
persons in SANUWAVE’s sole discretion.

 

3.

Payment. Concurrently with the
execution and delivery of this Deed by the Parties, JohnFK shall
pay to SANUWAVE the Equipment Payment and the Early Termination
Payment in US Dollars in a single installment by wire transfer of
immediately available funds to the designated account of
SANUWAVE.

 

4.

Representations and Warranties.
Each of the Parties represents and warrants that:

 

(i)

its execution,
delivery and performance of this Deed: (a) has been duly authorized
by all necessary corporate action of such Party; (b) does not
violate any provision of any of the governing documents of such
Party; (c) will not constitute a breach of or a default under (or
an event which with the giving of notice or the passage of time, or
both, would constitute such a breach of or default under) any
agreement, commitment, contract, instrument, mortgage, indenture,
lease or license, written or oral, to which such Party is a party
or to which it may be subject or by which it or any of its assets
may be bound; (d) will not violate any law or regulation applicable
to such Party; and (e) does not require the consent, approval or
waiver of or by any other person or entity or any governmental
authority, which consent, approval or waiver has not been obtained
in writing by such Party on or before the Effective Date;
and

 

(ii)

the Deed
constitutes the valid and legally binding agreement of such Party
enforceable against it in accordance with its terms, except as such
enforcement may be limited by applicable laws regarding bankruptcy,
insolvency or creditors’ rights generally or by general
principles of equity or limitations on the availability of
equitable relief.

 

5.

Liquidation Expenses. Each of
SANUWAVE and JohnFK shall be responsible for, bear and pay one-half
of the total aggregate fees, costs and expenses incurred in
connection with the winding down and liquidation of the
Company.

 

6.

Distribution Agreement.
Concurrently with the execution and delivery hereof, SANUWAVE and
JohnFK shall enter into a Distribution Agreement in substantially
the form attached hereto as Exhibit C (the
“Distribution
Agreement”).

 

7.

Release. Each Party, for itself
and its respective affiliates and subsidiaries and each of their
past, present and future agents, attorneys, representatives,
officers, directors, members, partners, shareholders, subsidiaries,
affiliates, successors and assigns, and the beneficiaries, heirs,
executors, administrators, and families of such persons
(collectively, “Releasors”), in
consideration of the releases herein provided by the other Parties,
does hereby release, waive, remise, and forever discharge each
other Party and such other Party’s respective predecessors
and its and their past, present and future agents, attorneys,
representatives, officers, directors, members, partners,
shareholders, subsidiaries, affiliates, successors and assigns, and
the beneficiaries, heirs, executors, administrators, and families
of such persons (collectively, “Releasees”) from all, and
all manner of, actions, causes of action, suits, bonds, bills,
covenants, controversies, agreements, promises, trespasses, damages
(whether general, special or punitive), judgments, executions,
claims and demands, indebtedness (either as principal obligor or as
surety or other accommodation party), liens, liabilities,
obligations, indemnities, costs, expenses, losses, attorneys’
fees and expenses (whether or not litigation is commenced), of
every kind and nature whatsoever, whether based in contract, tort,
or statutory liability, whether fixed or contingent, known or
unknown, suspected or unsuspected, foreseen or unforeseen
(“Claim” or
“Claims”), which any such
Releasor had, now has or may in the future have, arising under or
related to the JV, the JV Agreement and/or the transactions of the
Parties carried on thereunder or in connection therewith.
Notwithstanding the foregoing, nothing in this Section 7 shall
release any Releasor from (i) its or his obligations under this
Deed or the Distribution Agreement, (ii) any Claim arising under or
related to the winding down and/or liquidation of the Company, or
(iii) any breach or violation by a party after the Effective Date
of its confidentiality obligations under Section 6.2 of the JV
Agreement, which Section 6.2 the Parties agree shall survive the
execution and delivery of this Deed and the termination of the JV
Agreement.

 

8.

Governing Law. This Deed shall
be governed by and construed in accordance with the laws of
Singapore.

 

 

2

 

 

9.

Dispute Resolution. Any dispute
among the Parties or between any of them arising under or related
to this Deed shall be resolved in accordance with the provisions of
Section 8.2 of the JV Agreement, which provisions are hereby
incorporated by reference into this Deed.

 

10.

Entire Agreement. This Deed and
the Distribution Agreement represent the entire and final agreement
of the Parties with respect to the subject matter hereof and
thereof, and supersede and merge any and all prior agreements,
statements, promises and communications by, between or among the
Parties or any of them with respect to such subject
matter.

 

11.

Severability. Each and every
obligation under this Deed shall be treated as a separate
obligation and shall be enforceable as such. If a term of this Deed
is or becomes illegal, invalid or unenforceable in any respect
under any jurisdiction, that will not affect (i) the legality,
validity or enforceability in the jurisdiction of any other term of
this Deed or (ii) the legality, validity or enforceability in any
other jurisdictions of that or any other term of this Deed. Such
term shall be replaced or mutually acceptable provision, which
being valid, legal, enforceable comes closest to the intention of
the Parties underlying such illegal, invalid or unenforceable
provision.

 

12.

Notices. All communications, notices and disclosures
required or permitted by this Deed shall be in writing and shall be
deemed to have been given on the earlier of the date (a) when
delivered personally, by messenger, by overnight delivery service
or otherwise, or (b) when received via facsimile, telex or
other electronic transmission, in all cases addressed to the Party
to which it is intended at its address or telefacsimile number set
forth below, unless and until a Party notifies the other Party in
writing of a change:

 

If to SANUWAVE:

 

SANUWAVE Health,
Inc.

 

Attn:
Chief Financial Officer

 

3360
Martin Farm Road, Suite 100

 

Suwanee, GA
30024

 

Lisa.Sundstrom@sanuwave.com

 

If to JohnFK:

 

JohnFK
Medical, Inc.

 

Attn:
President

 

916
Zhongheng Road, Zhonghe District

 

New
Taipei City, Taiwan

 

Feikai.syu@fkshealth.com

 

If to the Company:

 

Holistic Wellness
Alliance Pte. Ltd.

 

6
Temasek Boulevard, #09-05

 

Suntec
Tower Four

 

Singapore
(038986)

 

13.

Counterparts. This Deed may be
executed in two or more counterparts, each of which shall be deemed
to be an original and all of which, taken together, shall
constitute one and the same instrument.

 

 

 

 

 

[The remainder of this page is intentionally left
blank]

 

 

3

 

 

IN
WITNESS WHEREOF, the Parties have caused this Deed of Termination
of Joint Venture Agreement to be executed by their duly authorized
representatives as of the Effective Date first written
above.

 

	
Signed,
Sealed and Delivered for and on behalf of:

 

SANUWAVE
HEALTH, INC.

 

By:
____________________________

 

Name:
Kevin A. Richardson II

 

Title:
Chief Executive Officer and

Chairman of the
Board of Directors

 

In
the presence of:

 

 

 

________________________________ 

Witness’
signature

Name:

	
Signed, Sealed and
Delivered for and on behalf of:

 

HOLISTIC
HEALTH INSTITUTE PTE. LTD

 

By:
____________________________

 

Name:

 

Title:

 

In
the presence of:

 

 

 

 

_____________________________

Witness’
signature

Name:

                                                                                    
                                                                                  

	
Signed, Sealed and
Delivered for and on behalf of:

 

JOHNFK
MEDICAL, INC.

 

By:
____________________________

 

Name:
Fei-Kai Syu

 

Title:
Chairman and Chief Executive Officer

 

In the
presence of:

 

 

 

 

___________________________________

Witness’
signature

Name:

 

 

 

 

 

4

 

 

 

 

 

 

 

 

 

 

 

 

 

EXHIBIT A

 

OUTSTANDING INVOICES

 

 

 

 

 

Invoice
20301 Dated October 31, 2018 for $6,050.00

 

 

 

Invoice
20329 Dated December 28, 2018 for $58,325.00

 

 

 

(see
attached)

 

 

 

 

 

 

5

 

EXHIBIT B

 

JOINT VENTURE TERMINATION PENALTY INVOICE

 

 

 

 

 

Invoice
20335 Dated April 11, 2019 for $50,000.00

 

 

 

(see
attached)

 

 

 

 

 

 

6

 

 

 

EXHIBIT C

 

FORM OF DISTRIBUTION AGREEMENT

 

 

 

 

 

(see
attached)

 

 

 

 

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]